Context Biopharma Inc.

Arno Therapeutics, Inc.

Ohio State Innovation Foundation

Uti Limited Partnership

Patheon Inc.

Stefan Proniuk

Alexander Zukiwski

Akaash Kumari Singh

Anh Thu Thi Pham

Ulf Tilstam

Harry G Brittain

Holger Rauter

Silvia Werner

Holger Bindernagel

Hermann M Schaetzl

Basant Abdulrahman

Sabine Gilch

Sathyanarayana Narasimha Murthy

Ferry Brands

Onapristone extended-release formulations and methods of administering onapristone extended-release formulations are provided. Onapristone extended-release formulations provide sufficient therapeutic activity as compared to immediate-release formulations with reduced potential for adverse side effects.

Onapristone extended-release compositions and methods

Methods and systems for making onapristone (ONA) using acidic hydrolysis and dehydration with sulfuric acid in an alcoholic solution are provided.

Methods for onapristone synthesis dehydration and deprotection

Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.

Amorphous onapristone compositions and methods of making the same

Methods and systems for making intermediates in the synthesis of onapristone are provided. Aspects include the photoconversion of onapristone synthesis intermediates using a narrow band frequency light source.

Methods of making onapristone intermediates

Drug delivery systems and compositions, comprising a glidant, that increase the bioavailability of biopharmaceutic class II, III, or IV active agents, and methods of making the same, are provided.

Drug delivery system to increase bioavailability

Compositions and methods for reducing the level of prions in a prion-infected cells or host by exposing prion infected cells, tissues and organs to AR-12 and the AR-12 analog AR-14 to reduce the prion level by at least about 90%.

Compositions and methods for reducing prion levels

Methods and compositions for enhancing transungual delivery of AR-12 comprising administering AR-12 and permeation enhancers are provided.

Methods and compositions for enhanced transungual delivery of AR-12

A drug delivery system is presented to increase the bioavailability of biopharmaceutic class II, III, or IV active agents.

Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties.

Growing community of inventors

Austin, TX, United States of America

Stefan Proniuk